Compare NUCL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUCL | KZIA |
|---|---|---|
| Founded | 2023 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.4M | 125.6M |
| IPO Year | 2026 | 2002 |
| Metric | NUCL | KZIA |
|---|---|---|
| Price | $2.71 | $5.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.22 |
| AVG Volume (30 Days) | 198.2K | ★ 241.7K |
| Earning Date | 10-13-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $258.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.08 | $4.86 |
| 52 Week High | $14.22 | $17.40 |
| Indicator | NUCL | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 15.03 | 28.38 |
| Support Level | N/A | $4.86 |
| Resistance Level | $6.58 | $14.85 |
| Average True Range (ATR) | 0.39 | 0.68 |
| MACD | -0.08 | -0.16 |
| Stochastic Oscillator | 0.50 | 9.86 |
Eagle Nuclear Energy Corp is a next-generation nuclear energy company that seeks to combine domestic uranium exploration and development with proprietary small modular reactor (SMR) technology. It holds rights to the mineable, measured, and indicated uranium deposit in the United States, known as the Aurora Uranium Project, located in southeastern Oregon. The Aurora Uranium Project includes the Aurora deposit, with an estimated resource of 32.75 million pounds (Indicated) and 4.98 million pounds (Inferred) of near-surface uranium, and the adjacent Cordex zone.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.